BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 33641219)

  • 1. CMV presenting as a skin growth in renal transplant patient.
    Bhandari G; Tiwari V; Gupta A; Jain S; Gupta P; Bhargava V; Malik M; Gupta A; Bhalla AK; Rana DS
    Transpl Infect Dis; 2021 Aug; 23(4):e13590. PubMed ID: 33641219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful treatment with foscarnet for ganciclovir-resistant cytomegalovirus infection in a kidney transplant recipient: A case report.
    Iwami D; Ogawa Y; Fujita H; Morita K; Sasaki H; Oishi Y; Higuchi H; Hatanaka K; Shinohara N
    Nephrology (Carlton); 2016 Jul; 21 Suppl 1():63-6. PubMed ID: 26970406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leflunomide as a rescue treatment in ganciclovir-resistant cytomegalovirus infection in a seronegative renal transplant recipient--a case report.
    Ciszek M; Mucha K; Foroncewicz B; Chmura A; Pączek L
    Ann Transplant; 2014 Jan; 19():60-3. PubMed ID: 24481271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of oral ganciclovir in prevention of cytomegalovirus infection in post-kidney transplant patients.
    Ahsan N; Holman MJ; Yang HC
    Clin Transplant; 1997 Dec; 11(6):633-9. PubMed ID: 9408699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of opportunistic infection in kidney transplant recipients with cytomegalovirus infection and associated outcomes.
    Jorgenson MR; Descourouez JL; Cardinale B; Lyu B; Astor BC; Garg N; Saddler CM; Smith JA; Mandelbrot DA
    Transpl Infect Dis; 2019 Jun; 21(3):e13080. PubMed ID: 30891915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of recurrent cytomegalovirus disease in renal and liver transplant recipients: effect of oral ganciclovir.
    Turgeon N; Fishman JA; Doran M; Basgoz N; Tolkoff-Rubin NE; Cosimi AB; Rubin RH
    Transpl Infect Dis; 2000 Mar; 2(1):2-10. PubMed ID: 11429003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of oral acyclovir or ganciclovir therapy after preemptive intravenous ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus seropositive renal and liver transplant recipients receiving antilymphocyte antibody therapy.
    Turgeon N; Fishman JA; Basgoz N; Tolkoff-Rubin NE; Doran M; Cosimi AB; Rubin RH
    Transplantation; 1998 Dec; 66(12):1780-6. PubMed ID: 9884276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early clinical manifestations and laboratory findings before and after treatment of cytomegalovirus infection in kidney transplant patients.
    Siddiqui WA; Al Salmi I; Jha A; Pakkyara A; Yasir M; Shaheen FAM
    Saudi J Kidney Dis Transpl; 2017; 28(4):774-781. PubMed ID: 28748879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistent Primary Cytomegalovirus Infection After Deceased Donor Kidney Transplant: Ganciclovir Susceptibility of Human Cytomegalovirus With UL97 D605E Mutation: A Case Report.
    Nawashiro Y; Shiraki K; Yamamoto S; Takizawa K; Sasada Y; Suehiro M; Miura K; Hattori M; Daikoku T; Hisano M
    Transplant Proc; 2018 Dec; 50(10):3932-3936. PubMed ID: 30577289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of invasive cytomegalovirus disease in solid organ transplant patients with ganciclovir.
    Dunn DL; Mayoral JL; Gillingham KJ; Loeffler CM; Brayman KL; Kramer MA; Erice A; Balfour HH; Fletcher CV; Bolman RM
    Transplantation; 1991 Jan; 51(1):98-106. PubMed ID: 1846255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A single-center experience with ganciclovir-resistant cytomegalovirus in lung transplant recipients: treatment and outcome.
    Reddy AJ; Zaas AK; Hanson KE; Palmer SM
    J Heart Lung Transplant; 2007 Dec; 26(12):1286-92. PubMed ID: 18096480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful use of oral ganciclovir for the treatment of intrauterine cytomegalovirus infection in a renal allograft recipient.
    Puliyanda DP; Silverman NS; Lehman D; Vo A; Bunnapradist S; Radha RK; Toyoda M; Jordan SC
    Transpl Infect Dis; 2005 Jun; 7(2):71-4. PubMed ID: 16150094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation.
    Becker BN; Becker YT; Leverson GE; Simmons WD; Sollinger HW; Pirsch JD
    Am J Kidney Dis; 2002 May; 39(5):1088-95. PubMed ID: 11979354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ganciclovir. An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients.
    Noble S; Faulds D
    Drugs; 1998 Jul; 56(1):115-46. PubMed ID: 9664203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Control of cytomegalovirus-associated morbidity in renal transplant patients using intensive monitoring and either preemptive or deferred therapy.
    Brennan DC; Garlock KA; Lippmann BA; Buller RS; Gaudreault-Keener M; Lowell JA; Miller SB; Shenoy S; Howard TK; Storch GA
    J Am Soc Nephrol; 1997 Jan; 8(1):118-25. PubMed ID: 9013456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of cytomegalovirus infection in simultaneous kidney-pancreas transplant recipients receiving tacrolimus, mycophenolate mofetil, and prednisone with ganciclovir prophylaxis.
    Lo A; Stratta RJ; Egidi MF; Shokouh-Amiri MH; Grewal HP; Kisilisik AT; Trofe J; Alloway RR; Gaber LW; Gaber AO
    Transpl Infect Dis; 2001 Mar; 3(1):8-15. PubMed ID: 11429034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cytomegalovirus infection in peptic ulcer in renal transplant recipient: a case report].
    Ishiguro S; Ikeda T; Shimamoto K; Tanji N; Ohoka H; Yokoyama M
    Nihon Hinyokika Gakkai Zasshi; 2004 Sep; 95(6):777-80. PubMed ID: 15508703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytomegalovirus polyradiculopathy of late onset in a young renal transplant recipient.
    Papasotiriou M; Papachristou E; Marangos M; Koukoulaki M; Savvidaki E; Kalliakmani P; Goumenos DS
    Clin Nephrol; 2013 Jul; 80(1):75-8. PubMed ID: 23803598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia.
    Gotti E; Suter F; Baruzzo S; Perani V; Moioli F; Remuzzi G
    Clin Transplant; 1996 Dec; 10(6 Pt 1):550-5. PubMed ID: 8996777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing cytomegalovirus prophylaxis in renal transplantation: single center experience.
    Varga M; Remport A; Hídvégi M; Péter A; Kóbori L; Telkes G; Fazakas J; Gerlei Z; Sárváry E; Sulyok B; Járay J
    Transpl Infect Dis; 2005 Jun; 7(2):63-7. PubMed ID: 16150092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.